Skip to content

Interest of FSL 2 in Recently Diagnosed Type 2 Diabetic Patients

Interest of Freestyle Libre 2 as a Tool for Therapeutic Education in Recently Diagnosed Type 2 Diabetics Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05676593
Acronym
FREEDIA
Enrollment
40
Registered
2023-01-09
Start date
2023-05-03
Completion date
2024-12-03
Last updated
2023-11-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endocrinology, Type 2 Diabetes

Keywords

Sensor, Therapeutic education, Diabete, Glucose

Brief summary

Therapeutic patient education (TPE) is a key element in the management of people living with type 2 diabetes. The benefit of therapeutic education (TPE) has been clearly established on glycaemic control. Continuous interstitial glucose monitoring (CGM) can be considered as a TPE tool for people living with diabetes. A direct reading of the effects of diet and physical activity on glycaemic levels could have an impact on the initiation and maintenance of therapeutic lifestyle modifications. The investigators therefore propose a prospective randomised study in 2 arms : * a group of people living with diabetes receiving standard TPE vs * a group of people living with diabetes receiving standard TPE + FSL 28 days Ourmain objective is to determine the benefit of CGM on HbA1c at 3 months between 2 arms

Detailed description

Main objective to the investigators is to determine the benefit of continuous interstitial glucose monitoring (by fresstyle 2) for 28 days coupled with standard TPE (Patient Therapeutic Education) vs standard TPE alone in newly diagnosed type 2 diabetics on HbA1c at 3 months. The secondary objectives are to evaluate the effect of the TPE coupled with FSL vs TPE alone on : * HbA1c at 6 months (assessment of persistence or not of a remote effect) * weight change at 3 and 6 months * other cardiovascular risk factors : variation in blood pressure, lipid profil at 3 and 6 months * eating behaviour/ eating habits at 3 and 6 months * treatment satisfaction, anxiety and quality of life scores

Interventions

The FSL will be placed on patient for 28 days to measure interstitial glucose

OTHERTherapeutic education

Therapeutic education

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

We therefore propose a prospective randomised study in 2 arms : * a group of people living with diabetes receiving standard TPE vs * a group of people living with diabetes receiving standard TPE + FSL 28 days Ourmain objective is to determine the benefit of CGM on HbA1c at 3 months between 2 arms

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* recently diagnosed diabete mellitus (\<1 an) treated by non medical therapeutics and/or metformine * \> 18 years old * initial glycated hemoglobin between 7 and 8.5%

Exclusion criteria

* Person whose physical and/or psychological health is severely impaired * Person deprived of his rights, person under guardianship or curatorship * Person deprived of liberty (by judicial or administrative decision) * Person who does not speak the French language * Absence of affiliation to/Not beneficiary of a Social Security scheme * Absence of written informed consent to participate in the study * Unable to understand the nature, purpose and methodology of the study * Bariatric surgery planned within 6 months of inclusion

Design outcomes

Primary

MeasureTime frameDescription
Rate of change in glycated hemoglobine at 3 months3 monthsbiological control of glycated hemoglobin in a laboratory

Secondary

MeasureTime frameDescription
Rate of change of the time in range, time above range and time below range6 monthsdata of the freestyle libre
Rate of change in glycated hemoglobin at 6 months6 monthsbiological control
Rate of change in weight in kgIn kg each 3,6 months
Quality of Life questionnarySet a score out of 100 (100 good good quality of life - 0 bad quality of life) performed at 3,6 monthsEQVOD - Scale of Quality of Life, Obesity and Dietetics
Rate of change arteriel pressureIn mmHg each 3,6 months
Concentration of of LDL cholesterolIn g/L each 3,6 months
Concentration of TriglycerideIn g/L each 3,6 months
Anxiety and depression scale questionnary14 questions (high score depression, anxiety - low score good health) performed at 3,6 monthsHAD - Hospital Anxiety and Depression scale
Eating behavior questionnaire33 questions (no scale, doctor's assessment of the answers) performed at 3,6 monthsDEBQ-Dutch Eating Behaviour Questionnaire

Countries

France

Contacts

Primary ContactSULTAN Ariane, PU-PH
a-sultan@chu-montpellier.fr+33467338402

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026